Literature DB >> 12554793

Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis.

Sonia Terrillon1, Thierry Durroux, Bernard Mouillac, Andreas Breit, Mohammed A Ayoub, Magali Taulan, Ralf Jockers, Claude Barberis, Michel Bouvier.   

Abstract

G protein-coupled receptor (GPCR) oligomerization is a growing concept that has emerged from several studies suggesting that GPCRs can form both homo- and heterodimers. Using both coimmunoprecipitation and bioluminescence resonance energy transfer (BRET) approaches, we established that the vasopressin V1a, V2, and the oxytocin receptors exist as homo- and hetero-dimers in transfected human embryonic kidney 293T cells. Each receptor protomer had a similar propensity to form homo- and heterodimers, indicating that their relative expression levels may determine the homo-/heterodimer ratio. The finding that immature forms of the receptor can be immunoprecipitated as homo- and heterodimers and the detection by BRET of such oligomer in endoplasmic reticulum-enriched fractions suggest that the oligomerization processes take place early during biosynthesis. Treatment with agonists or antagonists did not modify the BRET among any of the vasopressin and oxytocin receptor pairs studied, indicating that the dimerization state of the receptors is not regulated by ligand binding once they have reached the cell surface. Taken together, these results strongly support the notion that GPCR dimerization is a constitutive process.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12554793     DOI: 10.1210/me.2002-0222

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  77 in total

Review 1.  Roles of G-protein-coupled receptor dimerization.

Authors:  Sonia Terrillon; Michel Bouvier
Journal:  EMBO Rep       Date:  2004-01       Impact factor: 8.807

2.  Receptor activity-independent recruitment of betaarrestin2 reveals specific signalling modes.

Authors:  Sonia Terrillon; Michel Bouvier
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

3.  V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH.

Authors:  Brigitte Murat; Dominic Devost; Miriam Andrés; Julie Mion; Véra Boulay; Maithé Corbani; Hans H Zingg; Gilles Guillon
Journal:  Mol Endocrinol       Date:  2012-02-02

4.  Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.

Authors:  Maithé Corbani; Miguel Trueba; Stoytcho Stoev; Brigitte Murat; Julie Mion; Véra Boulay; Gilles Guillon; Maurice Manning
Journal:  J Med Chem       Date:  2011-03-23       Impact factor: 7.446

5.  Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes.

Authors:  Marta Busnelli; Aude Saulière; Maurice Manning; Michel Bouvier; Celine Galés; Bice Chini
Journal:  J Biol Chem       Date:  2011-11-08       Impact factor: 5.157

6.  Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET.

Authors:  Pascale G Charest; Sonia Terrillon; Michel Bouvier
Journal:  EMBO Rep       Date:  2005-04       Impact factor: 8.807

Review 7.  Oligomerization of G protein-coupled receptors: past, present, and future.

Authors:  Paul S-H Park; Slawomir Filipek; James W Wells; Krzysztof Palczewski
Journal:  Biochemistry       Date:  2004-12-21       Impact factor: 3.162

Review 8.  Monitoring the formation of dynamic G-protein-coupled receptor-protein complexes in living cells.

Authors:  Kevin D G Pfleger; Karin A Eidne
Journal:  Biochem J       Date:  2005-02-01       Impact factor: 3.857

Review 9.  Entropy and oligomerization in GPCRs.

Authors:  Rajkumar P Thummer; Matthew P Campbell; Mark K Dean; Marie J Frusher; Paul D Scott; Christopher A Reynolds
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

Review 10.  Computational methods in drug design: modeling G protein-coupled receptor monomers, dimers, and oligomers.

Authors:  Patricia H Reggio
Journal:  AAPS J       Date:  2006-05-12       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.